Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

1153 ArticlesStocks

1 / 116

Varroc Engineering: Not Quite Rocking

The listing of Varroc Engineering managed to benefit only the Tata Group. The IPO investors have lost more than three-fifths of their investments. Even the ...
Varroc-scaled.jpg

An “Experimental” Exit: IDFC Does What We Expected It To Do After an RBI Suggestion

A committee of the RBI has suggested that a bunch of changes be done to the Bank Licensing norms, which are very interesting in how they impact current banks ...
IDFC-scaled.jpg

A Special Situation Opportunity Only For Those That Don’t Pay Tax

In Capitalmind Premium, we run a bunch of "experimentals". These are ideas that may not apply to everyone equally, or may have a very short term focus, or have ...
Special-Situation-scaled.jpg

What’s the Story with IndiGo Valuations Flying High?

India's largest airline has gained the most globally among its peers in the last six months. The share prices are trading 18% higher compared to pre-covid ...
Featured-Image-1.jpg

The Pitfalls of Mid and Small Cap Investing

All investors want to own quality companies in their portfolios, these are all weather companies which if held over long periods of time give satisfactory ...
Group-3.jpg

How have Index Inclusions & Exclusions performed?

How does getting added to or getting removed from the NIFTY affect a stock's performance? Should you buy index inclusions for the passive inflows that will ...
Featured-Image-13.jpeg

The Market Loves Drugs & Tech; Hates Power and the Powerful

The performance of the Nifty 50 index has been patchy from last Samvat because of the outbreak of Covid-19. The lockdown imposed from the last week of March ...
markets-love-hate-sectors-min.jpg

Blockbuster Earnings backed by Strong Demand for Balkrishna Industries

Highlight of Balkrishna's 2nd quarter earnings Strong sales growth of 46% on the back of agricultural tyre ...
Earnings-Report-1.jpg

Gland Pharma IPO: Should you invest?

Hyderabad based Gland Pharma will be launching the biggest IPO in Indian Pharma sector on 9th November. It’s one of the fastest growing B2B player in the ...
Gland-pharma-Featured-image-2.jpg

A good quarter despite tepid sales growth for Dr Lal PathLabs

Dr Lal Pathlabs, a leading diagnostic company has come up with its Q2 Results. We look at the results and management commentary in this post. ...
Earnings-Report-1.jpg